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Objective: To analyze self-reported adherence to antiretroviral regimens containing ritonavir-
boosted protease inhibitors, nonnucleoside reverse transcriptase inhibitors (NNRTI), raltegravir, 
and maraviroc.
Methods: Overall, 372 consecutive subjects attending a reference center for HIV treatment 
in Florence, Italy, were enrolled in the study, from December 2010 to January 2012 (mean age 
48 years). A self-report questionnaire was filled in. Patients were defined as “nonadherent” if 
reporting one of the following criteria: ,90% of pills taken in the last month, $1 missed dose 
in the last week, spontaneous treatment interruptions reported, or refill problems in the last 
3 months. Gender, age, CD4, HIV-RNA, years of therapy, and type of antiretroviral regimen 
were analyzed with respect to adherence.
Results: At the time of the questionnaire, 89.8% of patients had ,50 copies/mL HIV-RNA 
and 14.2% were on their first combined antiretroviral therapy. 57% of patients were prescribed 
a regimen containing ritonavir boosted protease inhibitors (boosted PI), 41.7% NNRTI, 17.2% 
raltegravir, and 4.8% maraviroc; 49.5% of the subjects were on bis-in-die regimens, while 
50.5% were on OD regimens, with 23.1% of these on the single tablet regimen (STR): tenofovir/
emtricitabine/efavirenz. The nonadherence proportion was lower in NNRTI than in boosted-PI 
treatments (19.4% vs 30.2%), and even lower in STR patients (17.4%). In multivariable logis-
tic regression, patients with the NNRTI regimen (OR: 0.56, 95% CI: 0.34–0.94) and the STR 
(OR: 0.45, 95% CI: 0.22–0.92) reported lower nonadherence. Efavirenz regimens were also 
associated with lower nonadherence (OR: 0.42, 95% CI: 0.21–0.83), while atazanavir/ritonavir 
regimens were associated with higher nonadherence. No other relation to specific antiretroviral 
drugs was found. A higher CD4 count, lower HIV-RNA, and older age were also found to be 
associated with lower nonadherence, while a longer time on combined antiretroviral therapy 
was related to higher nonadherence.
Conclusion: STR maintains an advantage in improving adherence with respect to other 
combined antiretroviral therapies, even though new antiretroviral drugs and drug classes have 
become available in recent years.
Keywords: HIV , self-reported adherence, single tablet regimen, boosted protease inhibitors, 
nonnucleoside reverse-transcriptase inhibitors
Introduction
Combined antiretroviral therapy (cART) has changed the prognosis of most patients 
infected with HIV by decreasing morbidity and mortality.1 However, establishing a 
strong adherence to cART regimens remains a challenge for most patients.2,3 In addition, 
a comparison of results among different adherence studies will inevitably be biased 
because of the discrepancy between the employed definitions of adherence.
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Complex regimens decrease adherence,4 and thus main-
taining adherence above 95% was originally considered 
necessary to avoid virological failure,5 but most studies 
anticipated the use of ritonavir-boosted protease inhibitor 
(boosted PI) regimens in first-line therapy, or included a large 
number of patients in un-boosted PI regimens.6
Whether this high degree of adherence is necessary for 
regimens containing boosted PI and nonnucleoside reverse 
transcriptase inhibitors (NNRTI) is still being debated.7 
Recent studies have shown that an adherence to boosted PI 
greater than 80% may be sufficient.8,9 NNRTI could require 
even lower adherence rates than boosted PI,8 but the risk of 
acquiring NNRTI resistance is higher than for boosted PI.6 
Moreover, studies analyzing adherence in maraviroc and 
raltegravir regimens are lacking.
Given the expectation of improved adherence for recently 
released antiretroviral drugs, thanks to improved tolerability 
and better toxicity profiles, the goal was to measure the adher-
ence rate through self-reported adherence to antiretroviral 
regimens, including boosted PI, NNRTI, maraviroc, and 
raltegravir, and comparing the adherence in patients treated 
with different medications (twice daily [BID]; once-daily 
[OD]; and the single tablet regimen [STR]).
Methods
The study was conducted at the HIV clinic of Careggi Hos-
pital in Florence, Italy. A standard interview concerning a 
brief self-administered questionnaire10 was carried out at each 
medical visit, after signing informed consent, by consecutive 
HIV infected patients on stable cART, who accessed the site 
between December 2010 and January 2012. Only patients 
who had received at least 3 months of treatment with the 
current regimen were included in the study.
The following four measurements of adherence comprised 
the assessment: (1) the proportion of cART doses taken over 
the preceding month, as measured by a visual analog scale; 
(2) any missed doses over the past week; (3) spontaneous 
treatment interruption of two or more days in the past three 
months; and (4) a lack of drug refill after finishing the drug 
in the past 3 months. Therefore, a lack of just one correct 
behavior was defined as nonadherence, as follows: less 
than 90% of pills taken in the last month, one, or more than 
one missed dose in the last week, a spontaneous treatment 
  interruption, or refill problems in the last 3 months.
All clinical data were obtained by consulting the records of 
the hospital, including the demographic data, CD4 T-cell count, 
HIV-RNA values, Centers for Disease Control and Prevention 
(CDC) stages of clinical assessment, and therapeutic history.
Viral load and CD4 cell counts, collected within 3 months 
of filling out the questionnaire, were considered. Patients 
with viral loads lower than 50 copies/mL, in two consecutive 
measurements, were considered virologically suppressed.
Descriptive results are presented as proportions, medians, 
ranges, or 95% confidence intervals. Inferential statistics, for 
unadjusted assessment, used Fisher’s exact test to analyze 
categorical variables and the ANOVA test to analyze the 
continuous variables. Moreover, for multivariable assess-
ment, adjusted logistic regression was also used.
The multivariable models included nonadherence, as pre-
viously defined, as a dependent variable, as well as variables 
significantly associated with unadjusted analysis. Gender, 
age, CD4 cell count, log10 HIV-RNA, AIDS (CDC C3) diag-
nosis, and frequency of drug prescription (BID or OD) were 
all included as covariates, regardless of their significance in 
unadjusted analysis. Each antiretroviral drug, drug class, 
and STR was added to the adjusted analysis in order to test 
whether they were associated with nonadherence.
Results
Out of the 427 consecutive patients attending the center during 
the observation time, 372 (87.1%) were enrolled in the study (55 
patients did not complete the adherence questionnaire; 60% of 
these were women). About half of the patients refused to com-
plete the questionnaire (26 patients) because they reported that 
they were busy, while 20% were worried about their privacy.
The general characteristics of the included patients are 
described in Table 1. As shown, about one fourth had a pre-
vious AIDS diagnosis. Patients were generally pre-treated; 
indeed, only 14.2% were on for their first antiretroviral regi-
men. At the time of the questionnaire date, most of them (about 
90%) had undetectable HIV-RNA (,50 copies/mL).
The proportion of patients using each drug, drug class, 
and type of regimen is reported in Table 2. As shown, .90% 
of patients were in treatment with a cART regimen,   including 
Table 1 General characteristics of included patients
n (%) Median IQR
Male gender 287 (77.2)
Age (years) 47.7 (42.1–54.5)
CDC C3 91 (24.5)
CD4+ cell count (cells/μL) 602 (423.5–825)
Undetectable log10 hIV-RNA 334 (89.8)
hCV-positive 76 (20.4)
First line treatment 53 (14.2)
Overall duration of ART (months) 123 (55.2–173)
Duration of current cART (months) 19.2 (11.0–36.4)
Abbreviations: CDC, Center for Disease Control and Prevention; IQR, interquartile 
range; ART, antiretroviral therapy; cART, combined antiretroviral therapy.
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the NRTI backbone. As the third drug, boosted PI was 
the widest used, followed by NNRTI, integrase inhibitors 
(raltegravir), and CCR5 inhibitors (maraviroc). About half 
were on BID and half were on OD regimens. Less than one 
fourth were on a single tablet regimen: the co-formulation 
of tenofovir/emtricitabine/efavirenz in a single pill was the 
only one available at the time of the interview.
Table 2 shows, in the second column, the mean percent-
age of self-reported adherence in the last month before the 
interview (the first and main question of the questionnaire) 
by drug, drug-class, and type of medication (graphically 
summarized in Figures 1 and 2). Moreover, in the third col-
umn of Table 2 (and graphically summarized in   Figures 3 
and 4), the proportion of nonadherent patients is reported. 
The overall proportion of nonadherent patients was 25.5%, 
and the proportion of patients who failed adherence accord-
ing to the four adherence-defining questions is as follows: 
(1) less than 90% of pills taken in the last month: 8.1%; 
(2) one, or more than one, missed dose in the past week: 
12.4%; (3) spontaneous treatment interruption in the past 
three months: 7.3%; and (4) a lack of refill in the past 
3 months: 8.1%.
As shown, the largest percentage of pills taken in the 
previous month was reported by patients in treatment with 
efavirenz for NNRTI, with fos-amprenavir (though the 
number of patients in treatment with this drug was very low) 
and unboosted atazanavir for PI. STR had a high adherence 
percentage, as compared to the OD and BID regimens. 
Moreover, the PI-class and the NNRTI-class included in 
the regimen had a similar percentage of pills taken in the 
previous month, though with completely different results 
when considering nonadherent patients; with the Fisher 
exact test, the NNRTI class was found to be associated with 
lower nonadherence, while the PI class was associated with 
higher nonadherence.
Efavirenz was the only single drug associated with lower 
nonadherence; STR was also found to be associated with the 
Fisher exact test. Table 3 reports the multivariable association 
Table 2 Level of adherence according to the drugs or the type 
of regimen prescribed
n (%) Mean % pills  
taken in the  
past month
% nonadherent  
patients  
(P value)
Overall 372 (100) 96.4 25.5
NRTI backbone 335 (90.1) 96.5 26.0
Efavirenz 94 (25.3) 97.8 17.0 (P , 0.029)
Nevirapine 48 (12.9) 94.4 22.9
Etravirine 14 (3.8) 95.0 21.4
Lopinavir 53 (14.2) 96.8 34.0
Atazanavir 101 (27.2) 95.8 28.7
  Boosted 81 95.3 32.1
  Unboosted 20 98.0 15.0
Darunavir 42 (11.3) 95.7 31.0
  OD 32 95.9 31.3
  BID 10 95.0 30.0
fAPV/r 11 (3.0) 99.1 9.1
Maraviroc 18 (4.8) 96.1 16.7
Raltegravir 64 (17.2) 96.6 23.4
PI class 212 (57.0) 96.2 30.2 (P , 0.018)
NNRTI class 155 (41.7) 96.5 19.4 (P , 0.021)
BID regimen 184 (49.5) 96.2 26.1
OD regimen 188 (50.5) 96.6 25.0
STR 86 (23.1) 97.8 17.4 (P , 0.05)
Abbreviations: STR, single tablet regimen: tenofovir/emtricitabine/efavirenz; OD, 
once-daily; BID, bis-in-die; NNRTI, nonnucleoside reverse transcriptase inhibitor; 
NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
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Figure 1 Self-reported proportion of pills taken in the previous month, according to the main drug used.
Abbreviations: LPV/r, Lopinavir/r; ATV/r,  Atazanavir/ritonavir; DRV/r, Darunavir/ritonavir; NVP, Nevirapine; EFV, Efavirenz; ETV, Etravirine; RAL, Raltegravir; MVC, Maraviroc.
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a higher HIV-RNA and a longer time on cART were associ-
ated with higher nonadherence. HCV positivity, duration 
of current cART, and being on first line treatment were not 
associated with nonadherence in the unadjusted analysis, 
and therefore these were not included in the multivariable 
models.
Discussion
Monitoring and supporting adherence is of high importance 
for successful HIV treatment.11 Adherence was measured 
using a self-report questionnaire in an unselected sample 
of patients on steady cART; most of these patients (89.8%) 
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Figure 2 Proportion of patients reporting nonadherence, according to the main drug used (nonadherence defined as: ,90% pills taken in the past month; $1 missed dose 
in the past week; a lack of drug refill in the previous 3 months; or a spontaneous drug interruption in the previous 3 months).
Abbreviations: LPV/r, Lopinavir/r; ATV/r,  Atazanavir/ritonavir; DRV/r, Darunavir/ritonavir; NVP, Nevirapine; EFV, Efavirenz; ETV, Etravirine; RAL, Raltegravir; MVC, Maraviroc.
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Figure 3 Self-reported proportion of pills taken in the last month, according to the type of regimen used.
Abbreviations: PI, protease inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitors; BID, twice daily; OD, once-daily; STR, single tablet regimen.
of single drugs with nonadherence. Efavirenz was associated 
with lower nonadherence, while boosted atazanavir was 
associated with higher nonadherence.
The other drugs were tested, but no significant association 
was observed (data not reported in the table). No association 
was found for the OD or BID regimens. Similarly, Table 4 
reports the multivariable models for the NNRTI class and 
the STR, both of which are associated with lower nonadher-
ence. The PI class in the current regimen was not found to be 
associated with nonadherence in the multivariable analysis.
Finally, in all models, a higher age and a higher CD4 
cell count were associated with lower nonadherence, while 
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were virologically suppressed (HIV-RNA ,50 copies/mL) 
and/or in long-term treatment.
In our sample, the adherence level was high, which is 
possibly related to patients being in steady cART; moreover, 
self-reporting may overestimate the real level of adherence.1 
However, relying on patients to report adherence is the easiest 
and most common method used for measurement.
In order to overcome the shortcomings of self-reported 
adherence, several questions were used to improve the robust-
ness of the outcome: a “nonadherent” was defined as a subject 
who showed at least one nonadherence behavior, based on 
the the four questions included in the questionnaire.
After repeated testing, 90% of pills taken was chosen as 
the adherence cut-off point, derived from the assumption 
that with the recently released drugs (NNRTI, boosted PI, 
raltegravir, and maraviroc) this level would provide durable 
suppression. Indeed, recent reports have shown that durable 
viral suppression can be achieved using regimens that require 
adherence rates lower than 95%.12,13
No significant association was detected between non-
adherence and gender. In contrast, a younger age was con-
sistently associated with lower adherence to cART.14 Not 
surprisingly, a higher HIV-RNA and a lower CD4 count 
were associated with higher nonadherence, as was a longer 
time on cART, since (as previously observed) adherence may 
wane over time.15
The main finding of this analysis is related to the type 
of treatment. NNRTI treatment is associated with signifi-
cantly lower nonadherence than boosted PI. In particular, 
efavirenz was associated with lower nonadherence, while 
boosted atazanavir was associated with higher nonadherence. 
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Figure 4 Proportion of patients reporting nonadherence, according to the type of regimen (nonadherence defined as: ,90% of pills taken in the previous month;   
$1 missed dose in the previous week; a lack of drug refill in the previous 3 months; or a spontaneous drug interruption in the previous 3 months).
Abbreviations: PI, protease inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; BID, twice daily; OD, once-daily; STR, single tablet regimen.
Table 3 Adjusted logistic regression analysis for association with 
nonadherence in order to measure the effect of single drugs
Efavirenz 
OR (95% CI)
Boosted atazanavir 
OR (95% CI)
Male gender 0.88 (0.48–1.60) 0.89 (0.49–1.60)
Age (by year) 0.96 (0.93–0.99) 0.96 (0.94–0.99)
CDC C3 1.17 (0.66–2.06) 1.17 (0.67–2.07)
CD4 (by 50/μL) 0.99 (0.92–1.00) 0.96 (0.92–1.00)
Log10 hIV-RNA 1.73 (1.12–2.68) 1.73 (1.11–2.70)
Years of therapy (each) 1.07 (1.02–1.12) 1.07 (1.02–1.12)
OD regimen (vs BID) 1.61 (0.92–2.82) 0.94 (0.54–1.66)
Efavirenz 0.42 (0.21–0.83)
Boosted atazanavir 1.88 (1.01–3.54)
Abbreviations:  OD,  once-daily;  BID,  twice  daily;  CDC,  Centers  for  Disease 
Control and Prevention.
Table  4 Adjusted  logistic  regression  analysis  for  association 
with nonadherence in order to measure the effect of single drug 
classes
NNRTI 
OR (95% CI)
STR 
OR (95% CI)
Male gender 0.90 (0.50–1.64) 0.88 (0.47–1.60)
Age (by year) 0.96 (0.94–0.99) 0.96 (0.93–0.99)
CDC C3 1.16 (0.67–2.04) 1.14 (0.65–2.01)
CD4 (by 50/μL ) 0,96 (0.92–1.00) 0.96 (0.92–1.00)
Log10 hIV-RNA 1.66 (1.08–2.57) 1.69 (1.09–2.61)
Years of therapy (each) 1.07 (1.02–1.12) 1.07 (1.02–1.12)
OD regimen (vs BID) 1.23 (0.74–2.05) 1.60 (0.91–2.82)
NNRTI Class 0.56 (0.34–0.94)
STR 0.45 (0.22–0.42)
Abbreviations: STR, single tablet regimen: tenofovir/emtricitabine/efavirenz; OD, 
once-daily; BID, twice daily; NNRTI, nonnucleoside reverse transcriptase inhibitor; 
CDC, Centers for Disease Control and Prevention.
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However, the only available STR included efavirenz, so the 
improvement in adherence may be influenced more by STR 
than efavirenz. No significant differences were found when 
comparing the levels of adherence in patients on an OD 
regimen and a BID regimen. This partially contrasts with 
the results of a published meta-analysis, where adherence 
was modestly better with the OD regimen than with the BID 
regimen; this effect was more pronounced at the initiation 
of treatment and for regimens in which all medications were 
taken once per day.16
Our differing results could have several causes. First, 
most of the patients in this study were on long-term steady 
treatment, and thus as a result the study may include more 
adherent patients. Second, the BID regimens in our sample 
included raltegravir and maraviroc, which were found to be 
related to good, though nonsignificant, adherence levels.
Although data about symptoms were not collected, our 
data suggests that drugs with less toxicity, ie, still raltegra-
vir or maraviroc used to switch from OD to BID regimen, 
may not result in adherence problems or loss of virological 
efficacy.
According to previous studies, simplifying the regimen 
to STR improved the adherence to the cART,17 and even 
switching from the OD regimen to STR, using the same drug 
combination, led to better reported adherence and quality of 
life.18 Our analysis appears to confirm these results, with one 
strong point being that the BID, OD, and STR regimens were 
compared in an actual treatment scenario in which new and 
more tolerable drugs, such as darunavir, etravirine, maravi-
roc, and raltegravir, were available.
The study has several limitations. Analysis is based on 
cross-sectional rather than prospective data, and therefore no 
causal conclusions can be drawn. The majority of the patients 
were on steady cART, and proportion of nonadherence may 
differ in patients starting cART de novo. The selection might 
have excluded those who experienced early virological fail-
ure, disease progression, or defaulted from care.
In conclusion, older age, higher CD4 cell counts, lower 
HIV-RNA viral loads, and the use of STR are all related to 
lower nonadherence. In particular, the use of STR maintains 
an advantage in improving adherence with respect to other 
cARTs, even with the availability of new, well-tolerated 
antiretroviral drugs and drug classes in recent years.
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